RETAPAMULIN
|
|
|
- CAS-Nr.
- 224452-66-8
- Englisch Name:
- RETAPAMULIN
- Synonyma:
- CS-329;Retamole;SB-275833;Rebapamulin;RETAPAMULIN;tetapaMulin;Rui he Maureen;RetapaMulin API;Retapamulin, >=98%;RetapaMulin (SB-275833)
- CBNumber:
- CB32455623
- Summenformel:
- C30H47NO4S
- Molgewicht:
- 517.76
- MOL-Datei:
- 224452-66-8.mol
|
RETAPAMULIN Eigenschaften
- Siedepunkt:
- 594.9±50.0 °C(Predicted)
- Dichte
- 1.16±0.1 g/cm3(Predicted)
- storage temp.
- 2-8°C
- Löslichkeit
- insoluble in H2O; ≥114.8 mg/mL in EtOH; ≥16.15 mg/mL in DMSO
- Aggregatzustand
- solid
- pka
- 14.65±0.70(Predicted)
- InChIKey
- STZYTFJPGGDRJD-IFPFAXJDNA-N
- CAS Datenbank
- 224452-66-8(CAS DataBase Reference)
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H412 |
Schädlich für Wasserorganismen, mit langfristiger Wirkung. |
Langfristig (chronisch) gewässergefährdend |
Kategorie 3 |
|
|
P273, P501 |
|
| Sicherheit |
| P273 |
Freisetzung in die Umwelt vermeiden. |
| P501 |
Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
RETAPAMULIN Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Antibacterial retapamulin is a derivative of the natural
product pleuromutilin and was developed by Glaxo and approved
in the US in 2007 for the treatment of skin infections. It has a unique mechanism of action, inhibiting bacterial
protein synthesis by inhibiting the larger subunit of the ribosome,
and thus has no cross resistance to other antibacterial
agents.
Pleuromutilin is a tricyclic diterpenoid that was first isolated in 1951 from the edible mushroom Pleurotus mutilus. The first semisynthetic analogs tiamulin and valnemulin, developed for veterinary use, have been shown to interact uniquely with bacterial ribosomes by high affinity binding to a site on the 50S subunit. Binding to this site interferes with ribosomal peptidyl transferase activity, blocks P-site interactions, and prevents the evolution of active 50S ribosomal subunits. Retapamulin, the first pleuromutilin approved for human use, behaves similarly to selectively inhibit bacterial protein synthesis. This novel mechanism of action has been implicated in the lack of in vitro target-specific cross-resistance with other classes of antibiotics.
Verwenden
Retapamulin is a topical antibiotic, which binds to both E. coli and S. aureus ribosomes with similar potencies with Kd of 3 nM
Pharmazeutische Anwendungen
A semisynthetic pleuromutilin formulated as a 1% ointment
for topical use. It is active against staphylococci
(MIC 0.12 mg/L), including methicillin-resistant strains, and
against streptococci (MIC 0.03–0.25 mg/L), including Str.
pyogenes and Str. pneumoniae. Most enterococci and Gramnegative
bacilli are resistant. Propionibacteria are susceptible,
suggesting that it might be useful in acne. Early indications
suggest that resistance does not emerge readily, but experience
with veterinary pleuromutilins indicates that chromosomal
resistance may develop with extended use.
It is metabolized in the liver and rapidly excreted, precluding
use in systemic infection. Systemic exposure is said to be
low following topical application and it appears safe, but there
are few data on absorption through broken and unbroken skin.
Principal side effects noted include local irritation and occasional
allergic reactions. Licensed use is presently restricted to
the treatment of impetigo and uncomplicated skin infections.
Possible value in methicillin-resistant Staph. aureus (MRSA)
infection or carriage has not yet been established.
Nebenwirkungen
The most frequent adverse event was application site irritation, but other side effects, occurring in o2% of patients, included headache, diarrhea, nausea, and nasopharyngitis. While there are no contraindications, it is recommended that pregnant women only use retapamulin when the potential benefits outweigh the potential risks since animal reproductive studies are not always predictive of human response. Likewise, nursing mothers are cautioned about the unknown possibility of retapamulin excretion in breast milk.
RETAPAMULIN Upstream-Materialien And Downstream Produkte
Upstream-Materialien
8-Azabicyclo[3.2.1]octane-3-thiol, 8-Methyl-, (3-exo)-
2-[(Methylsulfonyl)oxy]acetic acid (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester
Tropine-3-mesylate
TiaMulin Related CoMpound A
Tropin
Downstream Produkte
RETAPAMULIN Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 220)Lieferanten
224452-66-8()Verwandte Suche:
- RETAPAMULIN
- RetapaMulin (SB-275833)
- (3aS,4R,5S,6S,8R,9R,9aR,10R)-2-(exo-8-Methyl-8-azabicyclo[3.2.1]octan-3-ylsulfanyl)acetic acid 5-hydroxy-4,6,9,10-tetraMethyl-1-oxo-6-vinylperhydro-3a,9-propanocyclopentacycloocten-8-yl ester
- RetapaMulin API
- tetapaMulin
- (1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetraMethyl-9-oxotricyclo[5.4.3.0^{1,8}]tetradecan-6-yl 2-{[(1R,3S,5S)-8-Methyl-8-azabicyclo[3.2.1]octan-3-yl]sulfanyl}acetate
- Rebapamulin
- SB-275833
- Acetic acid, 2-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester
- Retapamulin, >=98%
- Retamole
- CS-329
- RetapamulinQ: What is
Retapamulin Q: What is the CAS Number of
Retapamulin Q: What is the storage condition of
Retapamulin Q: What are the applications of
Retapamulin
- Rui he Maureen
- 3-(2,5-dioxopyrrolidin-7-yl)propanoicacid
- N-Boc-piperidine-5-carbaldehyde
- Acetonitrile,2,3'-(nitrosoimino)bis-
- (3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetramethyl-5-((3-(((3-exo)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl)thio)prop-1-en-2-yl)oxy)-7-vinyloctahydro-4,9a-propanocyclopenta[8]annulen-3(3aH)-one
- 224452-66-8
- 924452-66-8
- 22452-66-8
- C30H47NO4S
- C30H46NO4S
- Inhibitors
- API, Antibiotics
